New study indicate that a daily intake of Vitamin K2 significantly reduce the risk of developing or die of cancer
(Thomson Reuters ONE) -
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
Recent studies have suggested an anticarcinogenic effect of vitamin K2 on
prostate cancer of approx 50%, while no effect was found for K1. In a new study
from the researchers from the German Cancer Research Centre confirms and even
extents this effect: the potential benefits of vitamin K2 accounts for
overall-cancer risk in both men and women, whereas vitamin K1 shows no effect.
The findings, based on data from the 24,340 men and women taking part in the
prospective EPIC Heidelberg cohort, are published in this month's issue of the
American Journal of Clinical Nutrition*. All 24,340 participants (aged 35-64 y)
were free of cancer at enrollment and followed up for cancer incidence and
mortality. Dietary vitamin K intake was estimated from food-frequency
questionnaires. During a 10 year follow-up, 1755 incident cancer cases occurred,
of which 458 were fatal. Cancer risk reduction with increasing intake of vitamin
K2, mainly the long chain menaquinones such as NattoPharma's MenaQ7 was
recorded.
In general, the researchers found, the one quarter with the highest intakes of
vitamin K2 were 28% less likely to have died of any one of the 22 different
cancers than the one-quarter of men and women with the lowest intakes of the
vitamin. Subjects in the highest quartile of vitamin K2 had a 62% reduced risk
of lung cancer and lung cancer mortality. For prostate cancer this figure was
42% reduced risk.
"It is at least remarkable that cancer-prevention was found to occur at similar
intakes of vitamin K2 as the previously observed protection against
cardiovascular disease and mortality. Both for cancer protection and
cardiovascular disease prevention a nutritional dose of 45 micrograms per day
was found to show a significant effect, although probably more profound effects
may even be expected from higher doses" says Cees Vermeer, PhD, Associate
Professor of Biochemistry VitaK BV, Maastricht University.
The study has been appreciated by Leon Schurgers, PhD, from the Cardiovascular
Research Institute CARIM at the University of Maastricht and vice president of
NattoPharma, Oslo, Norway. "The anti-carcinogenic effect of K2 vitamins has been
suggested in several previous papers. The study of Nimptsch and colleagues
confirms and adds significant evidence that especially vitamin K2 have
anti-carcinogenic properties. The beauty of this paper is that the effect is
found at nutritional doses of vitamin K2" says Schurgers.
"The study is of great importance and indicates how important daily intake of
vitamin K2 (MenaQ7) is for a healthy life. MenaQ7 has already been shown to
prevent osteoporosis and inhibit vascular calcification. Now it is also related
to decrease in cancer risk and cancer mortality" says Morten Sundsto, CEO of
NattoPharma, he continues: "in this study it is shown again that only vitamin K2
has an effect whereas vitamin K1 has not. Since our food provides insufficient
amounts of vitamin K2, our product MenaQ7 will contribute significantly to
general health. We are working on both MenaQ7 supplements and foods enriched
with MenaQ7 to supply the population with adequate amounts of vitamin K2."
More information:
CEO Morten Sundstø
Phone: +47 950 61860
SOURCE:
American Journal of Clinical Nutrition, online March 24, 2010.
Reuters Health, March 31. 2010
*Dietary vitamin K intake in relation to cancer incidence and mortality: results
from the Heidelberg cohort of the European Prospective Investigation into Cancer
and Nutrition (EPIC-Heidelberg)(1,2,3)
(1) From the Division of Cancer Epidemiology German Cancer Research Center
Heidelberg Germany (KN SR RKJL); the Department of Nutrition Harvard School of
Public Health Boston MA (KN);the Institute of Epidemiology Helmholtz Zentrum
München Neuherberg Germany (JL).
(2) Supported by ECNIS (Environmental Cancer Risk, Nutrition and( )Individual
Susceptibility), a network of excellence operating( )within the European Union
6th Framework Program, Priority 5:( )"Food Quality and Safety" (contract no
513943).( )
(3) Address correspondence to J Linseisen, Institute of Epidemiology,(
)Helmholtz Zentrum München, German Research Centre for Environmental( )Health,
Ingolstädter Landstr. 1, D-85746 Neuherberg, Germany.( )E-mail:
j.linseisen(at)helmholtz-muenchen.de
)
About MenaQ7®
MenaQ7, the Natural Vitamin K2 is extracted from fermented soybeans with
guaranteed actives and stability, clinical substantiation and patents granted
and pending. MenaQ7 provides the Natural K2 Vitamin in a form of menaquinone-7,
the long chained molecule offering superior bioavailability and health effects
in low doses, which has been tied to both bone and cardiovascular health.
For more information on the health benefits of MenaQ7, please visit
www.menaq7.com
About NattoPharma
NattoPharma, Norway, is the exclusive international supplier and brand-owner of
MenaQ7, the most effective natural form of vitamin K2. Vitamin K2 (MK-7) was
recently amended by the EU commission to the list of legally added vitamins for
fortified food and food supplements. NattoPharma ASA is listed on the Oslo Axess
list at the Oslo Stock Exchange. The company has established an extensive
research and development program aimed at documenting the benefits of vitamin
K2. Please see further information on www.nattopharma.com
[HUG#1400614]
Unternehmensinformation / Kurzprofil:
Datum: 06.04.2010 - 09:06 Uhr
Sprache: Deutsch
News-ID 18586
Anzahl Zeichen: 0
contact information:
Town:
LYSAKER
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 262 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New study indicate that a daily intake of Vitamin K2 significantly reduce the risk of developing or die of cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
NattoPharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
